Fig. 10.
Coronary blood flow (A) and myocardial oxygen consumption (B) at rest and during exercise (Ex) in the absence and presence of the KATP channel inhibitor glibenclamide + the adenosine receptor blocker 8-phenytheophylline (8-PT) ± the nitric oxide synthase inhibitor [N-nitro-l-arginine (LNNA)] in conscious instrumented dogs. Myocardial oxygen consumption (C) and systolic wall thickening (D) vs. coronary blood flow with and without glibenclamide (Glib) + 8-PT and the vasodilator sodium nitroprusside (SNP) under baseline resting conditions [data from Duncker et al. (35) and Ishibashi et al. (61)]. *P < 0.05 vs. control. †P < 0.05 vs. glibenclamide + 8PT.